Meta-Analysis
doi: 10.1016/j.amjcard.2005.02.015.
Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)
Affiliations
- PMID: 15950574
- DOI: 10.1016/j.amjcard.2005.02.015
Item in Clipboard
Meta-Analysis
Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)
Am J Cardiol.
.
Abstract
We conducted a meta-analysis on 6 studies in 2,963 patients who had coronary artery disease and received a sirolimus-eluting stent or a bare metal stent for revascularization. Compared with bare metal stents, sirolimus-eluting stents did not appear to increase the risk for thrombosis up to 13.5 months after coronary intervention (risk ratio 0.49, 95% confidence interval 0.22 to 1.12, p = 0.09).
Similar articles
-
Prospective native coronary artery stenosis treated with sirolimus-eluting stent (ONASSIS) registry--acute results and mid-term outcomes: a single-center experience.J Invasive Cardiol. 2005 Aug;17(8):401-5. J Invasive Cardiol. 2005. PMID: 16079443
-
Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).Am J Cardiol. 2007 Jul 1;100(1):45-51. doi: 10.1016/j.amjcard.2007.02.051. Epub 2007 May 11. Am J Cardiol. 2007. PMID: 17599439
-
The influence of low (81 mg) versus high (325 mg) doses of ASA on the incidence of sirolimus-eluting stent thrombosis.J Invasive Cardiol. 2007 Jul;19(7):291-4. J Invasive Cardiol. 2007. PMID: 17620672
-
Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials.Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2. doi: 10.1001/archinternmed.2012.758. Arch Intern Med. 2012. PMID: 22529227 Review.
-
Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Expert Opin Emerg Drugs. 2009 Dec;14(4):561-76. doi: 10.1517/14728210903203808. Expert Opin Emerg Drugs. 2009. PMID: 19712016 Review.
Cited by
-
[Coronary stent thrombosis: what's new in 2011?].Herz. 2011 May;36(3):241-53. doi: 10.1007/s00059-011-3464-1. Herz. 2011. PMID: 21505933 German.
-
Liposomal simvastatin attenuates neointimal hyperplasia in rats.AAPS J. 2010 Jun;12(2):181-7. doi: 10.1208/s12248-010-9173-5. Epub 2010 Feb 9. AAPS J. 2010. PMID: 20143196 Free PMC article.
-
Stent thrombosis: understanding and managing a critical problem.Curr Treat Options Cardiovasc Med. 2012 Feb;14(1):91-107. doi: 10.1007/s11936-011-0155-4. Curr Treat Options Cardiovasc Med. 2012. PMID: 22193981
-
Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.JACC Cardiovasc Interv. 2011 Oct;4(10):1057-66. doi: 10.1016/j.jcin.2011.05.025. JACC Cardiovasc Interv. 2011. PMID: 22017929 Free PMC article. Review.
-
Role of magnolol in the proliferation of vascular smooth muscle cells.Herz. 2015 May;40(3):542-8. doi: 10.1007/s00059-014-4051-z. Epub 2014 Mar 6. Herz. 2015. PMID: 24595318
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
